Scientific Terms
Molecular Tumor Profiling Benefits Pediatric Cancer Patients, Study Finds
A prospective, multicenter study involving 345 children or young adults with cancer suggested tumor panel sequencing can help guide treatment, improve diagnoses, or inform prognoses.
MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib
The research will include preclinical and clinical studies of ROS1/NTRK inhibitor repotrectinib and MET inhibitor elzovantinib in several tumor types.
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.Â
Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo
The accelerated approval makes the combination available to patients with any refractory tumor harboring a BRAF V600E mutation, except for those with colorectal cancer.